Publication at Faculty of Medicine in Hradec Králové |
2017
Abstract
Nivolumab is one of the new immune chceck-point inhibitors that block a suppression of cytotoxic T-lymphocyte antitumour immunity. Nivolumab's antitumour activity was clinically confirmed in various malignancies, mainly in malignant melanoma, renal cell carcinoma, non-small-cell lung cancer, Hodgkin's lymphoma, etc.
Recently, nivolumab confirmed therapeutic effect in recurrent/metastatic head and neck cancer as well. Based on the results of randomized phase 3 trial CheckMate 141 nivolumab has become one of the standard treatment approaches in platinum refractory recurrent/metastatic squamous cell carcinomas of head and neck.